Document Detail

Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
MedLine Citation:
PMID:  16483267     Owner:  NLM     Status:  MEDLINE    
The control of oesophageal acid exposure through gastric acid inhibition, as the basis for gastro-oesophageal reflux disease (GERD) treatment, arose from the apparent pH dependency of erosive oesophagitis and relationship to GERD symptoms. The current perception is that reflux disease is an entirely acid-mediated condition, and antisecretory therapies, particularly proton pump inhibitors, are the treatment of choice for patients with erosive and non-erosive reflux disease. A positive patient response to an empiric trial of proton pump inhibitor (PPI) therapy, or the 'PPI test', is commonly suggested as a method of GERD diagnosis. Recent studies have modified our understanding of the relationship between oesophageal acid exposure and GERD pathology, manifestations and symptoms. Whereas the use of PPIs to reduce oesophageal acid exposure in patients with erosions is associated with increased healing rates, non-erosive reflux disease patients are less likely to have an abnormal oesophageal pH profile. Patterns of oesophageal acid exposure, particularly nocturnal oesophageal acid exposure, have been linked to increased disease severity. Non-acidic reflux and the effect of PPIs on this parameter, including bile reflux and the toxicity of bile acids, may also be an important factor in GERD. This article explores some of these assumptions, practices and relationships, including: the association between oesophageal acid exposure and erosive and non-erosive gastro-oesophageal reflux disease; the effect of PPIs on oesophageal acid exposure in erosive oesophagitis patients; the influence of nocturnal acid secretion in GERD and the use of PPIs to control this parameter; the relevance of the PPI test for reflux disease diagnosis; and PPI influence on non-acidic reflux.
P B Miner
Related Documents :
11379467 - Plasma nicotinic acid level in chloroquine treated rats.
15575867 - Review article: treatment for gastro-oesophageal reflux disease--lifestyle advice and m...
1550227 - Mechanism of regulation of glucose production by lipolysis in humans.
17273867 - Independently silencing two jar family members impairs levels of trypsin proteinase inh...
9919997 - Evaluation and optimisation of separation buffers for the determination of corticostero...
23731087 - Hyaluronic acid solution injection for upper and lower gastrointestinal bleeding after ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  23 Suppl 1     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-02-17     Completed Date:  2006-08-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  25-32     Citation Subset:  IM    
Oklahoma Foundation for Digestive Disease, Oklahoma City, OK 73104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Ulcer Agents / therapeutic use
Bile / physiology
Esophagitis, Peptic / etiology,  physiopathology
Esophagus / physiopathology
Gastric Acid / physiology
Gastric Acidity Determination
Gastric Emptying / drug effects
Gastroesophageal Reflux / complications,  drug therapy*,  physiopathology
Hydrogen-Ion Concentration
Proton Pumps / antagonists & inhibitors*
Stomach / pathology
Reg. No./Substance:
0/Anti-Ulcer Agents; 0/Proton Pumps

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease--Bilitec, in...
Next Document:  Review article: the role of acid suppression in patients with non-erosive reflux disease or function...